FOLH1 and posterior cortical atrophy: Nonetheless, clinical trials are not confined to PCa; PSMA-specific CAR T-cells are also being studied for the treatment of advanced or metastatic urothelial bladder cancer (NCT03185468) and relapsed and refractory neuroblastoma (NCT04637503).